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Abstract: The molecular characteristics of early-stage clear cell renal cell carcinomas (ccRCCs)
measuring ≤7 cm associated with poor clinical outcomes remain poorly understood. Here, we sought
to validate genes associated with ccRCC progression and identify candidate genes to predict ccRCC
aggressiveness. From among 1069 nephrectomies performed on patients, RNA sequencing was
performed for 12 ccRCC patients with aggressive characteristics and matched pairs of 12 ccRCC
patients without aggressive characteristics. Using a prospective cohort (ClinicalTrials.gov Identifier:
NCT03694912), the expression levels of nine genes (PBRM1, BAP1, SETD2, KDM5C, FOXC2, CLIP4,
AQP1, DDX11, and BAIAP2L1) were measured by reverse-transcription polymerase chain reaction
from frozen tissues, and their relation to Fuhrman grade was investigated in 70 patients with small
ccRCC (≤4 cm). In total, 251 genes were differentially expressed and presented fold changes with
p-values < 0.05; moreover, 10 genes with the greatest upregulation or downregulation in aggressive
ccRCC remained significant even after adjustment. We validated previously identified genes that
were associated with ccRCC progression and identified new candidate genes that reflected the
aggressiveness of ccRCC. Our study provides new insight into the tumor biology of ccRCC and will
help stratify patients with early-stage ccRCC by molecular subtyping.
Keywords: clear cell renal cell carcinomas; RNA sequencing; gene expression analysis; prognostic
biomarkers
1. Introduction
Approximately one-third of patients treated for localized clear cell renal cell carcinoma (ccRCC),
the most common subtype of RCC, relapse following surgery; moreover, 15% of these patients exhibit
metastatic potential, which can lead to death [1–3]. Tumor growth and changes in radiographic images
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are time-dependent predictors of poor oncological outcomes, whereas tumor grade, tumor necrosis,
and patient performance are subject to inter-observer variability [1–4]. Alternatively, multigene assays
may provide prognostic information beyond what is possible with traditional approaches and are now
included in standard treatment guidelines for some tumors [4].
Recently, three companion articles were published based on multicenter, prospective longitudinal
cohort studies on ccRCC patients, referred to as TRACERx Renal (tracking renal cell cancer evolution
through therapy). They provide insights into ccRCC, including its origin of complex genetic alterations,
evolution, and progression to metastasis [5–8]. More than 90% of ccRCC cases show inactivation of the
gene encoding the von Hippel-Lindau tumor suppressor on chromosome 3p. Additionally, mutations
in other tumor suppressor genes are associated with ccRCC tumorigenesis, including polybromo 1
(PBRM1), BRCA1-associated 1 (BAP1), and SET domain-containing 2 (SETD2). PBRM1 and BAP1
mutations are largely mutually exclusive, and BAP1 mutations are significantly associated with
high-grade, high-stage tumors that result in low survival [9]. Although mutations in lysine-specific
demethylase 5C (KDM5C) occur at a lower frequency, they are also associated with poor oncological
outcomes [10].
Forkhead box protein C2 (FOXC2) and cytoskeleton-associated protein-glycine (CAP-Gly) rich
domain-containing linker protein family member 4 (CLIP4) mutations were associated with early-stage
ccRCC and synchronous metastasis [3]. Furthermore, PBRM1, BAP1, and FOXC2 were shown
to be significantly associated with aggressive early-stage ccRCC through target sequencing and
immunohistochemistry in our previous study [11].
Presently, molecular profiling does not influence the decision-making processes for ccRCC,
and RNA sequencing (RNA-seq) data for aggressive early-stage ccRCC patients have not been
reported. Moreover, the association between candidate gene mutations and aggressiveness has also
not been reported. Hence, this study aims to identify the biomarkers associated with aggressive
early-stage ccRCC.
2. Results
2.1. Baseline Characteristics
Clinicopathologic characteristics of the patients included in this study (n = 24) have been
summarized in Table S2, and specific patient information is listed in Table 1. The mean tumor size was
4.9 ± 1.6 cm. Patients with aggressive ccRCC had no significant differences in age, BMI, tumor size,
Fuhrman grade, or invasion status when compared with those with non-aggressive ccRCC. Among
the 24 patients, six patients had synchronous metastasis to the lung (57.1%) and bone (42.9%). Seven
patients reported tumor recurrence after nephrectomy within a mean follow-up period of 25.3 months.
Cancer-specific death was reported for eight patients, with a mean survival time of 44.1 months.
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Table 1. Clinicopathological characterization of each patient.
Aggressiveness Patient ID Sex Age(yr)
Tumor Size
(cm)
Fuhrman
Grade
Invasion
(Perinephric/Sinus
Fat/Vascular)
Survival
Time a (m) Outcome
b Recurrence Site SynchronousMetastatic Site
N Pt0-1 M 67 1.6 3 N 41 ned
N Pt0-2 M 56 6.3 3 Y 36 ned
N Pt0-3 M 76 3.5 2 Y 32 ned
N Pt0-4 F 73 5.3 2 Y 92 ned
N Pt0-5 M 81 6.6 3 Y 17 ned
N Pt0-6 M 72 5.4 3 Y 77 ned
N Pt0-7 M 60 6.9 3 Y 59 ned
N Pt0-8 M 59 6.4 3 Y 63 ned
N Pt0-9 M 61 4.7 3 Y 58 ned
N Pt0-10 M 76 5.0 2 N 46 ned
N Pt0-11 M 65 4.4 2 N 32 ned
N Pt0-12 M 75 2.7 2 N 34 ned
Y Pt1-1 M 73 5.5 3 N 19 cd Lung
Y Pt1-2 M 73 6.9 4 Y 17 cd Lung
Y Pt1-3 M 60 5.1 3 Y 57 pd/cd Local recurrence, liver
Y Pt1-4 M 58 2.8 3 N 36 cd Bone
Y Pt1-5 M 74 1.6 2 N 48 pd/cd Lung, lymph nodes
Y Pt1-6 M 70 6.6 3 Y 38 pd/cd Liver, bone, lymphnodes
Y Pt1-7 M 61 6.7 3 Y 14 pd/cd Lung, liver Lung, bone
Y Pt1-8 M 54 4.8 2 Y 56 pd/cd Local recurrence
Y Pt1-9 M 66 4.2 2 N 20 ned Bone
Y Pt1-10 M 60 5.2 4 Y 78 pd Lung, bone
Y Pt1-11 M 70 3.5 2 N 58 pd Bone
Y Pt1-12 M 44 5.5 3 Y 31 ned Lung
a Survival time was defined as the time from nephrectomy until the patient’s death or the last time that the patient was known to be alive; b cd, cancer death; ned, no evidence of disease;
pd, progression of the disease.
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2.2. Results from the RNA-Seq Analysis
RNA-seq analysis generated 8266 × 106 base pairs (bp) from ccRCC with aggressive characteristics
and 7583 × 106 bp from ccRCC without aggressive characteristics. In total, 71.68 × 106 reads in ccRCC
with aggressive characteristics and 66.69 × 106 reads in ccRCC without aggressive characteristics were
mapped. There were no differences in the number of reads between the two groups, among which a
total of 12,636 genes were identified.
2.3. Differentially Expressed Genes
In total, 251 genes were differentially expressed with fold changes and p-values < 0.05;
153 upregulated genes and 98 downregulated genes had fold changes ≥2 in ccRCC with aggressive
characteristics when compared with matched ccRCC without aggressive characteristics (Figure 1 and
Figure S1). The ten genes that were most upregulated or downregulated in patients with aggressive
ccRCC and retained significance even after adjustment are summarized in Table 2 and represented as
box plots in Figure S2.
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expression) in aggressive clear cell renal cell carcinomas (ccRCC) patients (n = 12, red) versus matched
pairs of non-aggressive ccRCC patients (n = 12, blue) based on 251 differentially expressed genes.
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Table 2. Significantly upregulated/downregulated genes in clinical T1 stage with or without aggressive
characteristics (metastasis, recurrence, or cancer-specific death).
Upregulated
Gene
Symbol Gene Title
FPKM (Mean ± SD) Log2 Fold Change
p-Value a Adjusted p bRCC with
Aggressive
Characteristics
RCC without
Aggressive
Characteristics
(With
Aggressive/without
Aggressive
Characteristics)
MOCOS Molybdenumcofactor sulfurase 16.76 ± 15.41 1.40 ± 1.29 +3.77 9.29 × 10−6 1.66 × 10−2
RGPD8
RANBP2-like and
GRIP domain
containing 8
41.49 ± 35.62 6.51 ± 5.38 +2.78 3.67 × 10−5 4.59 × 10−2
BAIAP2L1 BAI1 associatedprotein 2 like 1 7.05 ± 3.39 2.18 ± 1.28 +1.87 2.18 × 10−6 7.98 × 10−3
DDX11 DEAD/H-boxhelicase 11 31.95 ± 13.09 14.25 ± 5.18 +1.32 2.55 × 10−6 7.98 × 10−3
Downregulated
Gene
Symbol Gene Title
FPKM (Mean ± SD) Log2 Fold Change
p-Value a Adjusted p bRCC with
Aggressive
Characteristics
RCC without
Aggressive
Characteristics
(With
Aggressive/without
Aggressive
Characteristics)
SLC16A9
Solute carrier
family 16 member
9
2.13 ± 2.51 11.90 ± 8.48 −2.41 5.91 × 10−6 1.48 × 10−2
FRAS1
Fraser
extracellular
matrix complex
subunit 1
3.15 ± 3.80 13.66 ± 6.60 −2.12 4.37 × 10−8 5.47 × 10−4
NPR3 Natriureticpeptide receptor 3 3.22 ± 3.37 12.53 ± 7.84 −1.88 3.61 × 10−5 4.59 × 10−2
AQP1
Aquaporin 1
(Colton blood
group)
11.02 ± 11.86 36.80 ± 17.38 −1.63 1.73 × 10−5 2.71 × 10−2
TMEM38B Transmembraneprotein 38B 2.74 ± 1.81 8.07 ± 2.70 −1.47 1.21 × 10−6 7.57 × 10−3
PRUNE2 Prune homolog 2 19.10 ± 9.42 49.39 ± 15.65 −1.24 8.48 × 10−6 1.66 × 10−2
FPKM, fragments per kilobase of exon per million fragments mapped; RCC, renal cell carcinoma; SD, standard
deviation; a p-values by nbiomTest function in DESeq2; b Adjusted p-values by the Benjamini–Hochberg algorithm.
Four genes were upregulated: molybdenum cofactor sulfurase (MOCOS), RANBP2-like and
GRIP domain containing 8 (RGPD8), brain-specific angiogenesis inhibitor 1 associated protein 2 like 1
(BAIAP2L1), and DEAD/H-box helicase 11 (DDX11). The six downregulated genes were solute carrier
family 16 member 9 (SLC16A9), fraser extracellular matrix complex subunit 1 (FRAS1), natriuretic
peptide receptor 3 (NPR3), aquaporin 1 (AQP1), transmembrane protein 38B (TMEM38B), and prune
homolog 2 (PRUNE2).
For the ten selected genes, a supervised hierarchical clustering analysis of patients with aggressive
ccRCC versus matched pairs of patients with non-aggressive ccRCC was performed and revealed
clustering of Pt1-4 and Pt1-9 in the non-aggressive ccRCC group (Figure S3).
We observed clear clusters distinguishing patients from the aggressive and non-aggressive ccRCC
groups, as determined by the principal component analysis (PCA; Figure 2).
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Figure 2. Principal component score plots. First and second principal component scores in patients
with aggressive ccRCC (n = 12, red) versus tc e tient pairs with non-aggressive ccRCC (n = 12,
blue) are plotted.
Pt1-1, Pt1-2, and Pt1-12 (lung metastasis group) were grouped separately from other patients, while
Pt1-4 and 9 (bone metastasis group) were not clearly sep ated from patients w th non-aggressive
ccRCC. The expression of ten genes was compared between the lung metastasis and bone metastasis
groups and other patients. Significant overexpression of MOCOS and BAIAP2L1 was observed in the
lung metastasis group (p < 0.001 and p = 0.012, respectively) (Figure S4). Mutations were found in
the six candidate genes (PBRM1 (11/24, 45.8%), BAP1 (6/24, 25.0%), SETD2 (24/24, 100.0%), KDM5C
(9/24, 37.5%), FOXC2 (6/24, 25.0%), and CLIP4 (8/24, 33.3%)) in more than 25% of the patients from our
cohort; Figure 3 provides a visual depiction of the frequency of target gene mutations in our cohort.
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There were no significant differences in the frequencies of the six candidate aggressiveness-
associated mutations in patients with aggressive ccRCC and those without aggressive ccRCC (Table S3);
however, for the patients with aggressive ccRCC, BAP1, KDM5C, and FOXC2 mutations were enriched
by two-fold, and CLIP4 mutations were enriched by three-fold, compared to that in patients without
aggressive ccRCC.
We further verified the expression of 16 genes from the TCGA ccRCC database using UALCAN
(Figure S5). Our results showed that 15 of the 16 genes (all except RGPD8) were differentially expressed
in ccRCC samples, compared to the normal kidney samples. Moreover, the expression levels of 13 out
of 16 genes (except RGPD8, NPR3, and KDM5C) differed according to the cancer stage.
2.4. Association between Oncological Outcomes and Expression of the 10 Newly Selected Genes
Cancer-specific survival (CSS) and recurrence-free survival (RFS) and their association with the
ten newly selected genes were analyzed. For CSS, patients with cancer-specific death presented higher
expression patterns of RGPD8, BAIAP2L1, and DDX11 and lower expression patterns of SLC16A9,
FRAS1, AQP1, TMEM38B, and PRUNE2, in both the univariate and multivariate analyses. For RFS,
those with cancer recurrence presented higher expression patterns of DDX11 and lower expressions of
TMEM38B and PRUNE2, in both the univariate and multivariate analyses. Genes that were significantly
associated with both CSS and RFS included DDX11, TMEM38B, and PRUNE2 (Table 3).
We have dichotomized the expression of DDX11, TMEM38B, and PRUNE2 as negative vs.
positive and evaluated their association with CSS and RFS. Patients who had DDX11-positive and
TMEM38B-negative tumors had significantly higher chances of cancer-specific death (odds ratio [OR]
49.000; 95% confidence interval [CI] 3.765–637.794) and recurrence (OR 28.000, 95% CI 2.399–326.735;
Table 4 and Table S4).
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Table 3. Comparison of target gene expression according to oncological outcomes (cancer-specific death and recurrence).
Cancer-Specific Death
FPKM (Mean ± SD) RCC with Cancer-SpecificDeath (n = 8)
RCC without Cancer-Specific
Death (n = 16) p-Value
a Multivariate OR (95% CI) p-Value b
MOCOS 16.4 ± 12.5 5.4 ± 12.4 0.054 - 0.093
RGPD8 47.6 ± 38.4 12.2 ± 17.5 0.036 1.048 (1.006–1.093) 0.026
BAIAP2L1 7.5 ± 4.0 3.2 ± 2.2 0.019 1.553 (1.088–2.215) 0.015
DDX11 34.3 ± 13.4 17.5 ± 9.3 0.002 1.130 (1.025–1.245) 0.014
SLC16A9 1.3 ± 2.3 9.9 ± 8.2 0.001 0.585 (0.362–0.946) 0.029
FRAS1 2.4 ± 2.5 11.4 ± 7.4 <0.001 0.741 (0.567–0.967) 0.028
NPR3 3.1 ± 3.4 10.3 ± 8.0 0.006 - 0.058
AQP1 11.3 ± 12.8 30.2 ± 19.7 0.023 0.926 (0.859–0.997) 0.042
TMEM38B 1.9 ± 1.2 7.2 ± 2.9 <0.001 0.277 (0.091–0.841) 0.024
PRUNE2 20.1 ± 8.5 41.3 ± 20.5 0.002 0.921 (0.854–0.993) 0.032
Recurrence
FPKM (Mean ± SD) RCC with Recurrence (n = 7) RCC without Recurrence (n = 17) p-Value a Multivariate OR (95% CI) p-Value b
MOCOS 9.5 ± 6.6 8.9 ± 15.4 0.921 - 0.917
RGPD8 65.5 ± 25.9 6.9 ± 6.0 0.001 - 0.996
BAIAP2L1 6.8 ± 3.0 3.7 ± 3.4 0.048 - 0.066
DDX11 36.0 ± 10.2 17.8 ± 10.6 0.001 1.140 (1.029–1.264) 0.012
SLC16A9 1.5 ± 2.1 9.3 ± 8.3 0.002 - 0.056
FRAS1 3.1 ± 2.8 10.6 ± 7.8 0.002 - 0.051
NPR3 2.9 ± 2.5 9.9 ± 8.1 0.004 - 0.073
AQP1 12.7 ± 13.0 28.5 ± 20.3 0.071 - 0.090
TMEM38B 2.5 ± 1.5 6.6 ± 3.4 0.001 0.579 (0.355–0.944) 0.028
PRUNE2 14.5 ± 7.9 42.4 ± 17.6 <0.001 0.788 (0.623–0.996) 0.047
Data are shown as mean ± SD; a p-value calculated using the t-test; b p-value calculated using logistic regression for multivariate analysis.
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Table 4. Expression of DDX11, TMEM38B, and PRUNE2 by oncological outcomes (cancer-specific death and recurrence).
Groups Dichotomized by the
Expression of DDX1, TMEM38B
and PRUNE2
Cancer-Specific Death
RCC with Cancer-Specific
Death (n = 8)
RCC without Cancer-Specific
Death (n = 16) p-Value
a Multivariate OR (95% CI) p-Value b
DDX11+ 7/8 (87.5%) 5/16 (31.3%) 0.027 - 0.065
TMEM38B− 8/8 (100.0%) 4/16 (25.0%) 0.001 - 0.998
PRUNE2− 7/8 (87.5%) 5/16 (31.3%) 0.027 - 0.065
DDX11+ and TMEM38B− 7/8 (87.5%) 2/16 (12.5%) 0.001 49.000 (3.765–637.794) 0.003
DDX11+ and PRUNE2− 6/8 (75.0%) 2/16 (12.5%) 0.005 21.000 (2.372–185.930) 0.006
Recurrence
RCC with Recurrence (n = 7) RCC without Recurrence (n = 17) p-Value a Multivariate OR (95% CI) p-Value b
DDX11+ 7/7 (100.0%) 5/17 (29.4%) 0.005 - 0.999
TMEM38B− 6/7 (85.7%) 6/11 (54.5%) 0.069 11.000 (1.061–114.086) 0.045
PRUNE2− 7/7 (100.0%) 5/17 (29.4%) 0.005 - 0.999
DDX11+ and TMEM38B− 6/7 (85.7%) 3/17 (17.6%) 0.004 28.000 (2.399–326.735) 0.008
DDX11+ and PRUNE2− 7/7 (100.0%) 1/17 (5.9%) <0.001 - 0.998
Data are shown as the number of patients (%); a p-value calculated using the chi-square test or Fisher’s exact test; b p-value calculated using logistic regression for multivariate analysis;
DDX11+, FPKM (fragments per kilobase of exon per million fragments mapped) > 20.0; TMEM38B−, FPKM < 5.0; PRUNE2−, FPKM < 32.0.
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Patients with DDX11-positive and TMEM38B-negative tumors had a median CSS of 42.5 months
(95% CI 28.3–56.7 months), which was substantially shorter than that of patients who had
DDX11-negative or TMEM38B-positive tumors, whose median CSS was 96.4 months (95% CI 76.0–96.8
months). The differences in CSS corresponded to a hazard ratio (HR) of 16.057 (95% CI 1.866–138.169,
p = 0.011; Figure 4). For RFS, patients with DDX11-positive and TMEM38B-negative tumors had a
median RFS of 27.3 months (95% CI 15.4–39.2 months), which was substantially shorter than that of
patients with DDX11-negative or TMEM38B-positive tumors, who presented a median RFS of 84.9
months (95% CI 71.9–97.8 months). The differences in RFS corresponded to an HR of 23.052 (95% CI
2.686–197.844, p = 0.004; Figure 4).
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2.5. Survival Analysis of 16 Genes
Using the Kaplan–Meier plotter database, the prognostic value of the 16 genes was evaluated
in 530 patients with ccRCC. We found that 13 of the 16 genes (MOCOS, BAIAP2L1, DDX11, CLIP4,
SLC16A9, FRAS1, NPR3, AQP1, PRUNE2, TMEM38B, PBRM1, BAP1, and SETD2) were related to
overall survival (OS) in patients with ccRCC (Figure S6). High expression of MOCOS, BAIAP2L1,
DDX11, and CLIP4, and low expression of SLC16A9, FRAS1, NPR3, AQP1, PRUNE2, TMEM38B,
PBRM1, BAP1, and SETD2, was significantly associated with poor OS (p < 0.05 for both). Expression of
RGPD8, KDM5C, and FOXC2 was not significantly associated with poor OS in patients with ccRCC.
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2.6. GO Analysis and KEGG Analysis of DEGs
DEGs were functionally classified into biological process (BP), cellular component (CC), and
molecular function (MF) categories (Figure S7). In the BP category, the top three most enriched
terms were “single-organism process,” “cellular process,” and “single-organism cellular process”
(Figure S7A). In the CC category, the top three most enriched terms were “cell part,” “cell,” and
“organelle” (Figure S7B). In the MF category, the top three most enriched terms were “binding,”
“protein binding,” and “ion binding” (Figure S7C). Moreover, the top three most enriched terms in the
KEGG analysis were “metabolic pathways,” “cell cycle,” and “complement and coagulation cascades”
(Figure S7D).
2.7. Validation of Target Genes Using Frozen Tissue PCR
Of the ten genes newly identified through RNA-seq analysis, AQP1, DDX11, and BAIAP2L1
were previously reported to be potent indicators of outcome in patients with ccRCC. We analyzed
the expression of these three genes along with that of the six genes previously identified by the
qRT-PCR analysis of frozen tissue samples. Our results showed that DDX11 expression and tumor size
were significantly greater in patients with high Fuhrman grade (3 and 4), both in the univariate and
multivariate analyses (Table S5).
3. Discussion
This is the first study to identify 251 DEGs in early-stage aggressive ccRCCs measuring ≤7 cm
using RNA-seq. Among the potential target candidate genes, BAP1, KDM5C, FOXC2, and CLIP4
mutations were enriched in patients with aggressive ccRCC. Among the DEGs identified in this study,
MOCOS, RGPD8, BAIAP2L1, and DDX11 were significantly upregulated; in contrast, SLC16A9, FRAS1,
NRP3, AQP1, TMEM38B, and PRUNE2 were significantly downregulated.
A panel of six genes (PBRM1, BAP1, SETD2, KDM5C, FOXC2, and CLIP4) was chosen for
mutational frequency analysis based on the clinical relevance of significantly mutated genes across all
ccRCC cohorts [12,13]. However, these six genes were not differentially expressed, perhaps because
our patient cohort included unique cases for which cancers exhibited aggressive characteristics, such as
synchronous metastasis, recurrence, or cancer-specific death, even though the clinical stage was
low. Moreover, small sample sizes would have affected this result. As in other large NGS studies,
PBRM1 mutation was identified in 45.8% patients. However, BAP1 mutation was observed in 25%
of patients, which is slightly higher than the value obtained in other studies, perhaps because our
cohort comprised patients with more aggressive ccRCC; we intentionally collected aggressive ccRCC
to pair with non-aggressive ccRCC. BAP1, a critical gatekeeper for disease progression, has a mutually
exclusive interaction with PBRM1, whereas the BAP1 mutation is associated with worse prognosis and
a higher Fuhrman grade than the PBRM1 mutation [7,14]. This finding was further supported by the
MSKCC cohort study where BAP1 mutations were associated with poor prognostic factors (higher
T stage, higher nuclear grade, large size, more necrosis), and the presence of metastatic disease at
presentation) [15].
SETD2 mutation was observed in all cases of ccRCC in our study, which diverges from other NGS
studies in which the frequency of SETD2 mutation was substantially lower (approximately 11%) [12,13].
However, Liu et al. reported a multicenter study in China that had evaluated radical nephrectomy cases,
wherein the SETD2 protein deficiency rate was 34.1%, although there may have been a discrepancy
between protein deficiency and gene mutation rates [16]. KDM5C mutations were found in less than
40% of the study population, compared to 3.8–6.8% reported in other NGS studies [12,13]. We believe
that this difference in KDM5C mutation frequency could result from selection bias because of the unique
group of patients who were defined as aggressive. However, owing to the intratumoral heterogeneity
(ITH), there could also have been a sampling bias. Moreover, gene mutation status was based on
Cancers 2020, 12, 222 12 of 17
multiple types of sequencing that only reflect the gene status of very circumscribed cancer lesions,
and thus could underestimate mutational rates [16].
The frequency of PBRM1 mutation was not different in ccRCC with and without aggressive
characteristics. BAP1, KDM5C, FOXC2, and CLIP4 mutations were enriched in aggressive ccRCC,
which was not statistically significant because of small sample sizes. This finding is similar to the
results of other studies that have reported an association between BAP1 and KDM5C mutations and
aggressiveness of tumors [9,10]. FOXC2, a gene known to be associated with tumor aggressiveness and
synchronous metastasis in ccRCC, based on our previous studies [2,11], was found to be associated
with aggressive characteristics of tumors in early-stage ccRCC, in the present study. The frequency of
PBRM1 mutation was similar between patients with aggressive and non-aggressive ccRCC, perhaps
because it is an early, essential event in tumorigenesis that does not impact clinical outcome, but instead
plays a principal role in tumor initiation. BAP1 mutation was more frequently observed in aggressive
ccRCC; BAP1 is believed to be associated with disease progression and a worse prognosis [17].
With regard to metastasis, the lung and bone were the two most common sites, with up to 60%
and 40% of patients having lung and bone metastasis, respectively [18]. A recent study suggests
that patients with bone metastases have an unfavorable prognosis; however, another study found no
prognostic differences between metastatic sites [19], although this remains controversial. According to
this study, synchronous bone metastatic patients were grouped with non-aggressive ccRCC patients,
while synchronous lung metastatic patients were grouped with the aggressive ccRCC group. These
results show that the early bone metastasis group genetically clusters with the less aggressive ccRCC
group and suggest that the prognosis of early bone metastasis ccRCC patients might not be bad,
although future studies are needed to verify this finding. The exact role of MOCOS and BAIAP2L1
in lung metastasis needs to be studied further, as these genes may help us understand differences in
metastatic potential in ccRCC and the prognostic value of different metastatic sites.
We included AQP1, DDX11, and BAIAP2L1 from the newly identified gene set because these were
previously associated with ccRCC or have a known relation to other tumors [20–22]. A prospective
study examining frozen tissue qRT-PCR of AQP1, DDX11, BAIAP2L1, and six previously identified
genes (PBRM1, BAP1, SETD2, KDM5C, FOXC2, and CLIP4) showed that expression of DDX11 was a
significant factor for predicting tumor aggressiveness based on Fuhrman grade. Bhattacharya et al.
demonstrated that inhibiting DDX11 in melanoma cells decreased proliferation and rapidly increased
apoptosis [21]. In the future, we will perform an in vitro and in vivo study using DDX11 since ccRCC
has similar tumor characteristics as melanoma.
We only included DDX11 and TMEM38B in our final analysis of CSS and RFS since although
using three genes increased the statistical significance (Table S4), the combination of DDX11 and
PRUNE2 was not associated with recurrence in the multivariate analysis (Table 4). Therefore, although
combining three genes would of course increase the statistical significance compared to two genes in
clinical settings, it is also important to reduce the number of genes used. Therefore, we tried to select
the most important gene that is both related to CSF and RFS.
We propose that the factors involved in tumor aggressiveness and metastasis or recurrence are
different. Previous studies have focused on using Fuhrman grade as the golden standard and have
compared gene expression or mutation based on Fuhrman grade. However, Fuhrman grade only
reflects cell differentiation and does not reflect metastatic and recurrence potential. Recent studies have
reported clonal and subclonal mutations in ccRCC, whereas clonal mutations are present in all tumor
regions, and subclonal mutations are present in some, but not all, tumors [23]. Clonal cancer evolution
is also known to be involved in ccRCC through Darwinian selection [23]. TRACERx Renal classified
tumors into seven distinct evolutionary subtypes [6,7], and primary tumors with low ITH, in addition
to a low fraction of the tumor genome affected by somatic copy-number alterations (SCNAs), had an
overall low metastatic potential. In contrast, primary tumors with low ITH but elevated SCNAs were
associated with rapid progression at multiple sites [7]. Thus, our knowledge regarding potential ccRCC
biomarkers for guiding intervention and surveillance has recently been dramatically expanded. Recent
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article by Wach et al. reported the RNA sequencing of collecting duct carcinoma, a rare renal cell
carcinoma subtype with a very poor prognosis and solute carrier (SLC) gene family (SLC3A1, SLC9A3,
SLC26A7, and SLC47A1) was included in the most downregulated genes [24]. According to this study
trend, our newly identified biomarkers may further aid in unraveling the evolutionary trajectories of
ccRCC tumor growth.
This study has a few limitations. First, this study intentionally collected aggressive cases of ccRCC;
thus, selection bias may have resulted in statistical differences from other NGS studies. However,
this collection method has benefits, including the examination of unique cases of interest to clinicians.
Second, because of the retrospective nature of this study, the study sample size was small; this limited
our ability to further investigate the ITH of primary tumors, although the ITH in ccRCC tumors,
including even small renal masses, may be substantial [1]. In future studies, we plan to overcome this
ITH limitation by analyzing the circulating tumor DNA in plasma. Third, RNA-seq was based only
on surgical FFPE samples and we could not provide validation results from a different independent
dataset. To overcome these limitations and validate our findings, a prospective clinical trial is now
underway (ClinicalTrials.gov Identifier: NCT03694912) that will include an examination of the mutation
profiles of the selected genes (PBRM1, BAP1, SETD2, KDM5C, FOXC2, CLIP4, MOCOS, BAIAP2L1,
DDX11, and AQP1) for aggressive ccRCC. However, our preliminary data obtained using frozen tissue
PCR show promising results for DDX11, and in vivo and in vitro studies on each gene are ongoing.
The demonstration of immunohistochemistry in selected genes would have provided the association
between RNA and protein. However, we have focused on the use of RNA expression profiles since it
is easier and faster to use in the clinical settings compared to immunohistochemistry. Nevertheless,
the protein expression profiles would provide more specific information regarding the role of selected
genes. Therefore, we are planning to include protein expression analysis in the future study.
4. Materials and Methods
4.1. Patients and Tissues
For this retrospective study, data were gathered from 1132 patients with ccRCC (≤7 cm) who
underwent radical and partial nephrectomy between January 2008 and December 2014. An aggressive
tumor was defined as a tumor exhibiting synchronous metastasis, recurrence, or cancer-specific death;
synchronous metastasis was defined as metastasis detected at or within three months of the primary
RCC diagnosis [25]. Twelve patients with aggressive ccRCC and 12 matched patients in terms of
gender, BMI, percentage of radical surgeries performed, clinical tumor sizes, and Fuhrman grades
with non-aggressive ccRCC were examined in order to adjust the confounding factors other than
aggressiveness of ccRCC. This study was approved by the Institutional Review Board of the Yonsei
University Health System (project no: 4-2013-0742).
We included patients with ccRCC (≤7 cm) treated with nephrectomy alone and for whom
formalin-fixed paraffin-embedded (FFPE) tumor tissue samples were available; we also included
patients who did not exhibit the typical characteristics of ccRCC. Specimens that were inappropriate
for molecular analysis were excluded, and clinicopathologic features were recorded for each patient
(Supplementary Method 1). Diameters of the primary tumors were measured using imaging modalities.
For validation analyses, we used a prospective cohort (ClinicalTrials.gov Identifier: NCT03694912)
sampled between November 2018 and July 2019 and included cases with small ccRCCs (≤4 cm). Data on
clinicopathologic features were included, as previously described in our retrospective study group.
The levels of six previously identified genes (PBRM1, BAP1, SETD2, KDM5C, FOXC2, and CLIP4),
plus three genes (AQP1, DDX11, and BAIAP2L1) among the ten newly identified genes, were considered
potent indicators of outcome in ccRCC patients according to a literature search. Gene expression was
measured by reverse-transcription polymerase chain reaction (qRT-PCR).
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4.2. Tissue Preparation
Formalin-fixed, paraffin-embedded (FFPE) sections from patients with ccRCC were obtained from
the archives of the Department of Pathology at Yonsei University College of Medicine (Seoul, Korea).
All cases were reviewed and classified by a urologic pathologist (N.H.C.). Non-tumor elements were
identified based on hematoxylin and eosin-stained slides from each sample by a urologic pathologist
(N.H.C.). The samples were subsequently cut into 20-µm sections before being transferred to an
extraction tube.
4.3. RNA Extraction and Sequencing
Briefly, for FFPE tissues, RNA was extracted from 20 µm sections using an FFPE RNeasy kit
(Qiagen, Gaithersburg, MD, USA), and 100 ng of RNA was used to construct a sequencing library using
a TruSeq RNA Access library prep kit (Illumina, San Diego, CA, USA) according to the manufacturer’s
protocols (Supplementary Method 2).
The sequencing libraries were quantified by the Kapa Biosystems Library Quantification Kit for
Illumina Sequencing platforms according to the qPCR Quantification Protocol Guide (KapaBiosystems,
Wilmington, MA, USA Cat #KK4854) and qualified by the TapeStation D1000 ScreenTape (Agilent
Technologies, Palo Alto, CA, USA Cat # 5067-5582). Indexed libraries were then submitted to
Illumina NovaSeq 6000 (Illumina), and paired-end (2 × 101 bp) sequencing was performed by
Macrogen Incorporated.
4.4. Analysis of RNA Sequencing—Differentially Expressed Gene (DEG) Selection
Paired-end sequencing reads from cDNA libraries (101 bp) were generated and the trimmed
reads were aligned to the reference human genome ([University of California Santa Cruz] UCSC hg19).
Transcriptome assembly of known transcripts, novel transcripts, and alternative splicing transcripts
was processed.
Based on the results of this processing, the abundance of transcript and gene expression was
calculated as read count (the number of reads mapping to a gene) or FPKM value (fragments per
kilobase of exon per million fragments mapped) per sample. To identify DEGs from aggressive and
non-aggressive ccRCC groups, genes with more than one sample of zero read count were pre-filtered.
We then measured the expression levels of 27,685 RefSeq genes and 12,636 genes (Supplementary
Method 3).
For DEGs, unsupervised hierarchical clustering analysis was performed with the complete linkage
method and Euclidean distance as a measure of similarity. Principal component analysis (PCA) was
performed to reduce the dimensionality of the data set by transforming it into a new set of variables to
summarize the data features process (Supplementary Method 3). All data analysis and visualization of
DEGs were conducted using R.3.5.1 (www.r-project.org).
4.5. Variant Calling
For variant calling of RNA-seq data, trimmed reads were aligned to the human genome (UCSC
hg19). The alignment of the reads used in this analysis was created through Split ‘N’ Trim, mapping
quality reassignment, indel realignment, and base recalibration process (Supplementary Method 4).
For our target gene list (PBRM1, BAP1, SETD2, KDM5C, FOXC2, and CLIP4), the frequency of
alterations in all samples was represented on the heatmap. Individual genes are represented as rows,
and individual patients are represented as columns.
4.6. qRT-PCR
Total RNA was extracted from frozen tissue samples using TRIzol® reagent (Ambion,
Life Technologies, Carlsbad, CA, USA), and 1 µg of total RNA was reverse-transcribed into first-strand
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cDNA using an iNtRon Maxime RT PreMix (Intronbio, Sungnam, Korea Cat No. 25081) according to
the manufacturer’s protocol (Supplementary Method 5).
4.7. GO Analysis and KEGG Analysis
Gene Ontology (GO) analysis per biological process (BP), cellular component (CC), and molecular
function (MF) for DEGs were performed based on Gene Ontology (http://geneontology.org/). KEGG
(Kyoto Encyclopedia of Genes and Genomes) pathway analysis for DEGs was also performed based
on the KEGG pathway (https://www.genome.jp/kegg/) database (Supplementary Method 6).
4.8. Validation of Gene Expression, Survival Analyses, and Statistical Analyses
UALCAN (http://ualcan.path.uab.edu) was used to validate the expression of ten newly identified
genes and six target genes according to the stage of the cancer. The Kaplan–Meier plotter database
(http://kmplot.com) was used to analyze the associations between 16 genes (10 newly identified and
six target genes) and overall patient survival. Additional details for statistical analyses are provided in
Supplementary Method 7.
5. Conclusions
In summary, we identified DEGs in aggressive early-stage ccRCC, defined as those with
synchronous metastasis, recurrence, or cancer-specific death, and found that MOCOS, RGPD8,
BAIAP2L1, and DDX11 showed significantly higher expression levels, whereas SLC16A9, FRAS1,
AQP1, TMEM38B, and PRUNE2 showed significantly lower expression levels compared to those in
non-aggressive ccRCC. Moreover, we verified previously known genes that are associated with tumor
aggressiveness by analyzing mutational frequency. Further research on these molecular biomarkers
may help stratify patients with early-stage ccRCC by molecular subtyping and aid in making clinical
decisions accordingly.
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